脏缩有效降低CKD患者的血压
Agnes Bosch1, Dennis Kannenkeril1, Roland E Schmieder1
1Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Clinical kidney journal
|June 10, 2025
概括
脏缺血显示出治疗慢性病 (CKD) 患者不受控制的高血压的前景. 需要进一步的研究,特别是在高级CKD,但目前的数据表明它.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 高血压加速慢性病 (CKD) 的进展.
- 许多CKD患者有耐药高血压,尽管药物治疗.
- 目前的治疗方法不足以解决同情神经活动.
研究的目的:
- 审查高血压慢性病患者损的证据.
- 评估脏化对血压和功能控制的安全性和有效性.
主要方法:
- 临床试验和关于脏缩的观察性研究的综述.
- 对高血压CKD患者群体的安全性和疗效数据的分析.
主要成果:
- 目前的数据表明,对慢性脏病中不受控制的高血压而言,脏脱皮是安全有效的.
- 新出现的证据将其定位为一个有前途的额外治疗选择.
- 研究表明,它改变了同情神经活动.
结论:
- 脏缩是高血压CKD患者的潜在治疗选择.
- 进一步的随机对照试验是必要的,以确认有效性,特别是在晚期的CKD.
- 该程序解决了血压和功能中的一个关键因素,这种因素不能完全通过药物来控制.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
506
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
506
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
Antihypertensive Drugs: Action of Diuretics
627
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
627
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
490
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
490
Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2


